Molecular glue degraders: Lilly, AbbVie sign billion-dollar deals; BMS leads with three late-stage drugs

Data Compilation
#PharmaFlow

Pipeline Prospector Feb 2025: Bain buys Mitsubishi Tanabe for US$ 3.4 bn; Japan’s Ono gets FDA nod for rare joint tumor drug

Stock Recap
#PipelineProspector

Tamax

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

33 API Suppliers, 11 USDMF, 6 CEP/COS, 4 JDMF, 4 KDMF, 13 NDC API, 20 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

13 Drugs in Development

13 Drugs in Development

INTERMEDIATES

8 Intermediate Suppliers

8 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

127 FDF Dossiers, 26 FDA Orange Book, 54 Europe, 6 Canada, 14 Australia, 9 South Africa, 18 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - EQ 10MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 20MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, SOLUTION;ORAL - EQ 20MG BASE/10ML

RELATED EXCIPIENT COMPANIES

2 EUROAPI, 3 Rochem International Inc, 18 SPI Pharma, 7 DKSH, 7 Faran Shimi Pharmaceutical, 4 Boai NKY Pharmaceuticals Ltd, 6 Gangwal Healthcare, 4 Nanjing Well Pharmaceutical, 1 Pfanstiehl, 1 ACG Worldwide, 5 Actylis, 7 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 24 BASF, 1 Bioplus Life Sciences, 1 Clariant, 10 Corel Pharma Chem, 6 DFE Pharma, 2 Finar, 7 Gangwal Chemicals, 5 Ideal Cures Pvt Ltd, 4 Ingredion Pharma Solutions, 37 Kerry, 4 Kima Chemical, 6 Lonza Capsugel, 17 Microlex e.U, 2 Nomisma Healthcare, 2 Novo Excipients, 2 Pharmatrans-Sanaq, 8 Pluviaendo, 4 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 28 Roquette, 7 Seppic, 7 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 2 Shijiazhuang Huaxu Pharmaceutical, 10 Sigachi Industries, 3 The Dow Chemical Company, 1 Ulanqab Kema New Material, 1 Valens Pharmachem, 3 Vasa Pharmachem, 1 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

87 Fillers, Diluents & Binders, 51 Coating Systems & Additives, 32 Direct Compression, 28 Thickeners and Stabilizers, 27 Controlled & Modified Release, 26 Granulation, 25 Disintegrants & Superdisintegrants, 22 Taste Masking, 20 Film Formers & Plasticizers, 18 Solubilizers, 17 Co-Processed Excipients, 17 Chewable & Orodispersible Aids, 15 Parenteral, 14 Topical, 13 Lubricants & Glidants, 10 Rheology Modifiers, 5 Empty Capsules, 5 API Stability Enhancers, 5 Emulsifying Agents, 4 Vegetarian Capsules, 4 Coloring Agents, 2 Surfactant & Foaming Agents, 1 Soft Gelatin

DIGITAL CONTENT

1 Data Compilation #PharmaFlow, 24 News #PharmaBuzz

GLOBAL SALES INFORMATION

2 US Medicaid Prescriptions, 53 Regulatory FDF Prices

MARKET PLACE

6 APIs, 9 FDF Dossiers

REF. STANDARDS & IMPURITIES

3 EDQM, 1 USP, 1 Others

$ Xls download

Filters

Last Updated on PharmaCompass	Virtual Booth	Country	Registrant Name	MF Registration No.	Classification	Initial Date of Reg.	Latest Date of Reg.	Registrant's Address
28/03/2025	Seqens	France	PCAS S.A.	218MF10150	Tamoxifen citrate	2006-01-31	2008-04-21	21, chemin de la Sauvegarde 21 Ecully Parc - CS 33167 69134 Ecully Cedex France
28/03/2025	Excella GmbH	Germany	Excella GmbH & Co. K.G.	306MF10097	Tamoxifen citrate	2024-07-11	2024-07-11	NUERNBERGER STRASSE 12, 90537 FEUCHT, GERMANY

Tamax

Tamax

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

33 API Suppliers

11 USDMF

6 CEP/COS

4 JDMF

4 KDMF

13 NDC API

20 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

13 Drugs in Development

INTERMEDIATES

8 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

127 FDF Dossiers

26 FDA Orange Book

54 Europe

6 Canada

14 Australia

9 South Africa

18 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - EQ 10MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - EQ 20MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

SOLUTION;ORAL - EQ 20MG BASE/10ML

RELATED EXCIPIENT COMPANIES

2 EUROAPI

3 Rochem International Inc

18 SPI Pharma

7 DKSH

7 Faran Shimi Pharmaceutical

4 Boai NKY Pharmaceuticals Ltd

6 Gangwal Healthcare

4 Nanjing Well Pharmaceutical

1 Pfanstiehl

1 ACG Worldwide

5 Actylis

7 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

24 BASF

1 Bioplus Life Sciences

1 Clariant

10 Corel Pharma Chem

6 DFE Pharma

2 Finar

7 Gangwal Chemicals

5 Ideal Cures Pvt Ltd

4 Ingredion Pharma Solutions

37 Kerry

4 Kima Chemical

6 Lonza Capsugel

17 Microlex e.U

2 Nomisma Healthcare

2 Novo Excipients

2 Pharmatrans-Sanaq

8 Pluviaendo

4 Prachin Chemical

1 Qianhao Chemical (Hebei) Co., Ltd

1 Qualicaps

28 Roquette

7 Seppic

7 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

1 Shanghai Welltone Material Technology Co., Ltd

2 Shijiazhuang Huaxu Pharmaceutical

10 Sigachi Industries

3 The Dow Chemical Company

1 Ulanqab Kema New Material

1 Valens Pharmachem

3 Vasa Pharmachem

1 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

87 Fillers, Diluents & Binders

51 Coating Systems & Additives

32 Direct Compression

28 Thickeners and Stabilizers

TABLET;ORAL - EQ 10MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL - EQ 20MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons